3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
13
Carcinoma, Hepatocellular
7
Neoplasms
3
Liver Neoplasms
2
Glioblastoma
2
Gastrointestinal Stromal Tumors
2
Colonic Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Piebaldism
1
Patient Compliance
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Microsatellite Stable Metastatic Colorectal Cancer
1
Meningioma
1
Melanoma
1
MCRC
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Liver Metastases
1
Leiomyosarcoma
1
Interventions
tislelizumab
1
regorafenib
1
Trace amine-associated receptor 1
1
Thymalfasin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
MCRC
×
regorafenib
×
Clear all
NCT06829355
2025-02-17
THYMI
Beijing Friendship Hospital
Phase 2
Recruiting
52 enrolled